Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Robert S Busch

Showing results (21-30 of 29) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 29 results.
Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists|April 2, 2011
Efficacy of teriparatide in patients with resolved secondary hyperparathyroidism due to vitamin D deficiencyAndrea N Traina, Michael P Kane, Gary Bakst, et al.
The Journal of Pharmacy Technology : Jpt : Official Publication of the Association of Pharmacy Technicians|December 3, 2021
Weekly Exenatide Therapy: A Real-World Comparison of Incretin TherapiesSara J Micale, Shahabodin Khatounabadi, Michael P Kane, et al.
The Lancet. Diabetes & Endocrinology|June 19, 2018
Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): a multicentre, open-label, randomised trialKatherine R Tuttle, Mark C Lakshmanan, Brian Rayner, et al.
Diabetes Care|July 29, 2025
Effects of Semaglutide With or Without Concomitant Mineralocorticoid Receptor Antagonist Use in Participants With Type 2 Diabetes and Chronic Kidney Disease: A FLOW Trial Prespecified Secondary AnalysisPeter Rossing, George Bakris, Vlado Perkovic, et al.
BMJ Open|July 16, 2024
Study protocol for a prospective, multicentre study of hypercortisolism in patients with difficult-to-control type 2 diabetes (CATALYST): prevalence and treatment with mifepristoneRalph A DeFronzo, Richard J Auchus, Irina Bancos, et al.
JACC. Advances|February 17, 2026
Investigating Endogenous Hypercortisolism Prevalence in a U.S. Population With Resistant Hypertension: MOMENTUM Rationale and DesignJorge Plutzky, Pam R Taub, Deepak L Bhatt, et al.
Diabetes Care|June 23, 2025
Inadequately Controlled Type 2 Diabetes and Hypercortisolism: Improved Glycemia With Mifepristone TreatmentRalph A DeFronzo, Vivian Fonseca, Vanita R Aroda, et al.
Diabetes Care|April 18, 2025
Prevalence of Hypercortisolism in Difficult-to-Control Type 2 DiabetesJohn B Buse, Steven E Kahn, Vanita R Aroda, et al.
The Lancet. Diabetes & Endocrinology|February 23, 2026
Efficacy and safety of relacorilant for the treatment of patients with Cushing's syndrome (GRACE): a multicentre, phase 3, double-blind, placebo-controlled, randomised-withdrawal studyRosario Pivonello, Giorgio Arnaldi, Richard J Auchus, et al.
Pageof 3

Showing results (21-30 of 29) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 29 results.
Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists|April 2, 2011
Efficacy of teriparatide in patients with resolved secondary hyperparathyroidism due to vitamin D deficiencyAndrea N Traina, Michael P Kane, Gary Bakst, et al.
The Journal of Pharmacy Technology : Jpt : Official Publication of the Association of Pharmacy Technicians|December 3, 2021
Weekly Exenatide Therapy: A Real-World Comparison of Incretin TherapiesSara J Micale, Shahabodin Khatounabadi, Michael P Kane, et al.
The Lancet. Diabetes & Endocrinology|June 19, 2018
Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): a multicentre, open-label, randomised trialKatherine R Tuttle, Mark C Lakshmanan, Brian Rayner, et al.
Diabetes Care|July 29, 2025
Effects of Semaglutide With or Without Concomitant Mineralocorticoid Receptor Antagonist Use in Participants With Type 2 Diabetes and Chronic Kidney Disease: A FLOW Trial Prespecified Secondary AnalysisPeter Rossing, George Bakris, Vlado Perkovic, et al.
BMJ Open|July 16, 2024
Study protocol for a prospective, multicentre study of hypercortisolism in patients with difficult-to-control type 2 diabetes (CATALYST): prevalence and treatment with mifepristoneRalph A DeFronzo, Richard J Auchus, Irina Bancos, et al.
JACC. Advances|February 17, 2026
Investigating Endogenous Hypercortisolism Prevalence in a U.S. Population With Resistant Hypertension: MOMENTUM Rationale and DesignJorge Plutzky, Pam R Taub, Deepak L Bhatt, et al.
Diabetes Care|June 23, 2025
Inadequately Controlled Type 2 Diabetes and Hypercortisolism: Improved Glycemia With Mifepristone TreatmentRalph A DeFronzo, Vivian Fonseca, Vanita R Aroda, et al.
Diabetes Care|April 18, 2025
Prevalence of Hypercortisolism in Difficult-to-Control Type 2 DiabetesJohn B Buse, Steven E Kahn, Vanita R Aroda, et al.
The Lancet. Diabetes & Endocrinology|February 23, 2026
Efficacy and safety of relacorilant for the treatment of patients with Cushing's syndrome (GRACE): a multicentre, phase 3, double-blind, placebo-controlled, randomised-withdrawal studyRosario Pivonello, Giorgio Arnaldi, Richard J Auchus, et al.
Pageof 3